Literature DB >> 7930469

Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years.

T C Mahl1, W Shockcor, J L Boyer.   

Abstract

We extended by 10 years, a follow-up study of 279 patients with primary biliary cirrhosis initially evaluated at the Yale Liver Study Unit between 1955 and 1979. Thirty-six patients (13%) were asymptomatic at the time of diagnosis. Accurate follow-up survival data were available for 247 patients (89%), ranging up to 24 years after the original diagnosis. Median predicted survival of patients in this study from the time of diagnosis is twice as long for patients who present without symptoms compared to symptomatic patients (16 vs 7.5 years, p < 0.0001). However, overall survival of those asymptomatic patients is shorter than that predicted for an age- and gender-matched control population (p < 0.0001), a difference that became apparent only after 11 years of follow up. With a median follow up of 12.1 years, 33% of the asymptomatic patients remained free of symptoms of liver disease, However, once symptoms develop, their survival is similar to those presenting with symptoms. Independent predictors of diminished survival include: elevated bilirubin, increasing age, ascites, advanced fibrosis and the degree of portal bile stasis on liver biopsy. It was not possible to predict which asymptomatic patients would remain symptom free.

Entities:  

Mesh:

Year:  1994        PMID: 7930469     DOI: 10.1016/s0168-8278(05)80139-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  25 in total

Review 1.  Primary biliary cirrhosis: new perspectives in diagnosis and treatment.

Authors:  M I Prince; D E Jones
Journal:  Postgrad Med J       Date:  2000-04       Impact factor: 2.401

2.  Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.

Authors:  M I Prince; A Chetwynd; W L Craig; J V Metcalf; O F W James
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

3.  Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis.

Authors:  C Rigamonti; L M Shand; M Feudjo; C C Bunn; C M Black; C P Denton; A K Burroughs
Journal:  Gut       Date:  2005-09-08       Impact factor: 23.059

4.  Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population.

Authors:  Junichi Kubota; Fusao Ikeda; Ryo Terada; Haruhiko Kobashi; Shin-ichi Fujioka; Ryoichi Okamoto; Shinsuke Baba; Youichi Morimoto; Masaharu Ando; Yasuhiro Makino; Hideaki Taniguchi; Tetsuya Yasunaka; Yasuhiro Miyake; Yoshiaki Iwasaki; Kazuhide Yamamoto
Journal:  J Gastroenterol       Date:  2009-06-27       Impact factor: 7.527

Review 5.  Primary biliary cirrhosis. Is (and how much of) the pathology preventible?

Authors:  Y Bar-Dayan; M E Gershwin; Y Levi; H Amital; Y Shoenfeld
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 6.  A brief review on prognostic models of primary biliary cholangitis.

Authors:  Sha Chen; Weijia Duan; Hong You; Jidong Jia
Journal:  Hepatol Int       Date:  2017-09-14       Impact factor: 6.047

Review 7.  Primary biliary cirrhosis and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara
Journal:  Intractable Rare Dis Res       Date:  2012-05

Review 8.  Geoepidemiology and changing mortality in primary biliary cholangitis.

Authors:  Annarosa Floreani; Atsushi Tanaka; Christopher Bowlus; Merrill Eric Gershwin
Journal:  J Gastroenterol       Date:  2017-04-01       Impact factor: 7.527

9.  Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Authors:  Runalia Bahar; Kimberly A Wong; Chung H Liu; Christopher L Bowlus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

10.  Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients.

Authors:  Theodoros A Zografos; Nikolaos Gatselis; Kalliopi Zachou; Christos Liaskos; Stella Gabeta; George K Koukoulis; George N Dalekos
Journal:  World J Gastroenterol       Date:  2012-09-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.